FDA continues prowl for COVID-19 product claims with warning letter to 8th CBD company

Last Updated on

FDA continues prowl for COVID-19 product claims with warning letter to 8th CBD company

Since the beginning of March, federal food and drug regulators have issued warning letters to 64 companies for selling products under claims that they will prevent, treat, mitigate diagnose or cure COVID-19.

To date, the U.S. Food and Drug Administration had sent eight of those letters to CBD companies, including:

May 26: CBD Gaze, a Puerto Rico-based company
May 15: Noetic Nutraceuticals, Columbia, Maryland; in corrective status
May 7: Agro Terra, d/b/a Patriot Hemp Company, Lyons, Colorado
April 16: Nova Botanix, d/b/a CanaBD, London, United Kingdom
April 7: CBD Online Store, Laguna Hills, California; in corrective status
April 6: Native Roots Hemp, Algoma, Wisconsin; in corrective status
April 6: Indigo Naturals, Carmel Valley, California
March 31: Neuro XPF, Las Vegas, Nevada; in corrective status

According to the FDA’s website tracking warning letters to firms marketing products related to coronavirus, the agency continues to actively monitor for “any firms marketing products with fraudulent COVID-19 prevention and treatment claims.

The site includes information for reporting websites that illegally sell human drugs, animal drugs, medical devices, biological products, foods, dietary supplements and cosmetics.

The agency said action against companies making false or misleading claims will include warning letters, product seizures or injunctions against products and firms or individuals who violate the law.

Source Link: https://hempindustrydaily.com/fda-continues-prowl-for-covid-19-product-claims-with-warning-letter-to-8th-cbd-company/

We are not the original authors of this article. This content was republished from HempIndustryDaily.com.

[placid_image]

Leave a Reply

Your email address will not be published. Required fields are marked *